Home » Stocks » Zomedica Pharmaceuticals

Zomedica Pharmaceuticals Corp. (ZOM)

Stock Price: $0.168 USD -0.057 (-25.20%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 52.66M
Revenue (ttm) n/a
Net Income (ttm) -10.56M
Shares Out 292.02M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $0.168
Previous Close $0.225
Change ($) -0.057
Change (%) -25.20%
Day's Open 0.160
Day's Range 0.155 - 0.180
Day's Volume 287,550,278
52-Week Range 0.110 - 0.499

More Stats

Market Cap 52.66M
Enterprise Value 52.67M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 292.02M
Float 137.88M
EPS (basic) -0.1
EPS (diluted) -0.10
FCF / Share -0.13
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.15M
Short Ratio 0.15
Short % of Float 2.99%
Beta 0.04
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 12.42
Revenue n/a
Operating Income -10.49M
Net Income -10.56M
Free Cash Flow -15.46M
Net Cash -7,167
Net Cash / Share 0.00
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -119.25%
ROE -29,421.11%
ROIC -550.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$0.50*
Low
0.50
Current: 0.168
High
0.50
Target: 0.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue----
Operating Income-19.79-16.65-8.08-5.73
Net Income-19.78-16.65-8.07-5.74
Shares Outstanding10693.4487.4080.16
Earnings Per Share-0.19-0.18-0.09-0.07
Operating Cash Flow-15.63-11.15-7.09-4.56
Capital Expenditures-0.16-0.62-0.17-0.23
Free Cash Flow-15.79-11.77-7.26-4.79
Cash & Equivalents0.511.943.453.23
Total Debt---0.01
Net Cash / Debt0.511.943.453.22
Assets4.186.035.224.58
Liabilities2.092.380.830.74
Book Value2.103.664.393.83
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Zomedica Pharmaceuticals Corp.
Country United States
Employees 28
CEO Robert Cohen

Stock Information

Ticker Symbol ZOM
Stock Exchange NYSE American
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSEAMERICAN: ZOM

Description

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.